PriceTracker GLP-1

What FDA’s record states

FDA record for the warning letter to Lean Rx, Inc. dba SkinnyRx
FieldWhat FDA’s record statesSource
RecipientLean Rx, Inc. dba SkinnyRxFDA letter
LocationSacramento, CAFDA letter
Letter dateFeb 20, 2026FDA letter
Posted by FDAMar 3, 2026FDA index
Issuing officeCenter for Drug Evaluation and Research (CDER)FDA letter
SubjectFalse & Misleading Claims/Misbranded (Telehealth)FDA letter
MARCS-CMS number717989FDA letter
GLP-1 drugs namedSemaglutide, TirzepatideFDA letter
Response letterNot published by FDAFDA letter
Closeout letterNot published by FDAFDA letter
“As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].”FDA warning letter to Lean Rx, Inc. dba SkinnyRx, Feb 20, 2026 · read the full letter on fda.gov ↗

What this is and is not.A warning letter is FDA’s statement of what it considers significant violations. It is an allegation, not a court finding, and the firm can respond. A closeout letter is posted when FDA confirms the violations were corrected.

A program we track

SkinnyRx appears on our price board. Its page shows what it charges and what we verified about it, including this record. SkinnyRx: prices and checks

Other GLP-1 letters FDA issued that week

And 17 more in the full list.

Source

Every field above is copied from FDA’s page for this letter, read Oct 3, 2026. The letter on fda.gov ↗ · All 161 GLP-1 warning letters